NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer

Title: NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer

Volume: 14 Issue: 3

Author(s): Marco A. Calzado, Susanne Bacher and M. Lienhard Schmitz

Affiliation:

Keywords: Inflammation, cancer, NF-κB, Inhibitor, IκB, IKK, Transcription factor

Abstract: The NF-κB/Rel signaling system is a paradigm for gene activation in response to inflammatory and menacing stimuli. Given the growing body of evidence showing an important involvement of NF-κB for the onset of autoimmune diseases and different types of cancer, NF-κB is an important drug target for the adjuvant therapy of these diseases. Great efforts have been made for the development of highly specific NF-κB inhibitors, some of them being currently tested in phase II clinical trials. Here we discuss recent progress in the identification of druggable components of the NF- κB signaling system and the development and potential use of novel NF-κB inhibitors.

Cite this article as:

Calzado A. Marco, Bacher Susanne and Schmitz M. Lienhard, NF-κB Inhibitors for the Treatment of Inflammatory Diseases and Cancer, Current Medicinal Chemistry 2007; 14 (3) . https://dx.doi.org/10.2174/092986707779941113